|1.||Matsumura, Y: 2 articles (11/2004 - 07/2001)|
|2.||Ueno, H: 1 article (11/2004)|
|3.||Yamada, Y: 1 article (11/2004)|
|4.||Shimada, Y: 1 article (11/2004)|
|5.||Okusaka, T: 1 article (11/2004)|
|6.||Ikeda, M: 1 article (11/2004)|
|7.||Hamaguchi, T: 1 article (11/2004)|
|8.||Watanabe, N: 1 article (11/2004)|
|9.||Muro, K: 1 article (11/2004)|
|10.||Ura, T: 1 article (11/2004)|
07/06/2001 - "NK911 has a small particle size of about 40 nm in diameter that accumulates in tumor tissue by EPR effect showing much stronger activity than the free DOX. "
10/01/2002 - "It has been suggested that Doxil can deliver DXR to a solid tumor more efficiently than NK911 via the EPR (enhanced permeability and retention) effect, because Doxil may be more stable in plasma than NK911. "
10/01/2002 - "In drug distribution experiments using an in vitro solid tumor model, when spheroids formed from two human colonic cancer lines, HT-29 and WiDr, and a human stomach cancer line, MKN28, were exposed to NK911, DXR was distributed throughout the spheroids, including their center. "
10/01/2002 - "On the other hand, DXR packed in NK911 may be distributed by diffusion to cancer cells distant from the tumor vessel, because NK911 can leak out of the tumor vessel and may be able to release free DXR more easily than Doxil. "
|3.||Stomach Neoplasms (Stomach Cancer)
|5.||Colonic Neoplasms (Colon Cancer)
|2.||glucuronyl glucosamine glycan sulfate (Vessel)